Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984528 | 0.90 | GPR119 (0.49) | GPR119HDAC1USP30TP53LMNA | |
| SCHEMBL5086233 | 0.87 | GPR119 (0.52) | GPR119HDAC1USP30 | |
| SCHEMBL3983576 | 0.86 | LTA4H (0.40) | GPR119TP53 | |
| SCHEMBL3987089 | 0.86 | GPR119 (0.59) | GPR119 | |
| SCHEMBL14191024 | 0.84 | GPR119 (0.66) | GPR119HDAC1TP53 | |
| SCHEMBL3987206 | 0.83 | GPR119 (0.53) | GPR119HDAC1LMNA | |
| SCHEMBL16466490 | 0.81 | USP30 (0.48) | GPR119USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL5083436 | 0.81 | USP30 (0.45) | GPR119HDAC1USP30 | |
| SCHEMBL3984822 | 0.80 | ALDH1A1 (0.48) | GPR119USP30TP53PTPN2PTPN1 | |
| SCHEMBL14191000 | 0.80 | GPR119 (0.55) | GPR119HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885HDAC1 2847/4885USP30 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.